Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.05.2023 | Case report

Dupilumab/prednisolone

Various toxicities: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat McKenzie PL, et al. Experience using dupilumab for pediatric atopic dermatitis at a tertiary care c enter: Inadequate response and adverse events. Pediatric Dermatology 38: 1178-1184, No. 5, 13 Sep 2021. Available from: URL: http://doi.org/10.1111/pde.14799 McKenzie PL, et al. Experience using dupilumab for pediatric atopic dermatitis at a tertiary care c enter: Inadequate response and adverse events. Pediatric Dermatology 38: 1178-1184, No. 5, 13 Sep 2021. Available from: URL: http://​doi.​org/​10.​1111/​pde.​14799
Metadaten
Titel
Dupilumab/prednisolone
Various toxicities: 4 case reports
Publikationsdatum
01.05.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-38407-7

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Posaconazole

Case report

Zoledronic-acid

Case report

Benralizumab

Case report

Nivolumab